Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and…

Overview of attention for article published in BMC Medicine, October 2017

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (65th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

policy: 1 policy source
twitter: 2 X users

reddit: 1 Redditor

Readers on

mendeley: 125 Mendeley

Summary Policy documents X Reddit

So far, Altmetric has seen 2 policy documents that reference this research output.

Tecentriq for Non-Small Cell Lung Cancer – Details

Cited by Canadian Agency for Drugs and Technologies in Health on 13 Sep 2019

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Cancer Immunotherapy After Adjuvant Immunotherapy: Clinical Effectiveness and Guidelines

Cited by Canadian Agency for Drugs and Technologies in Health on 06 Aug 2019

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.